Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

Article

You might want to recommend this clinical trial to your patients with metastatic melanoma which evaluates whether preparatory chemotherapy followed by infusion of DMF5 cells is a safe and effective for shrinking melanoma tumors.

Study Type: InterventionalAge/Sex Requirement: 18 years+ (None)

Sponsor: National Cancer Institute

ClinicalTrials.gov Identifier: NCT00924001

Purpose: To determine whether preparatory chemotherapy followed by infusion of DMF5 cells is a safe and effective for shrinking melanoma tumors. The primary outcomes measure is clinical response according to RECIST criteria and toxicity. The secondary outcomes measure is the rate of repopulation of young TIL cells as well as correlates that predict in vivo persistence and clinical response.

Click here to learn more about this clinical trial.

Related Videos
Shauna Applin, ARNP, an expert on HIV
Shauna Applin, ARNP, an expert on HIV
Linda Stein Gold, MD, and Bruce Strober, MD, PhD
Ralph DeFronzo, MD | Credit: UT San Antonio
Signs and Symptoms of Connective Tissue Disease
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
3 KOLs are featured in this program.
3 KOLs are featured in this program.
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
A panel of 4 experts on HIV
© 2024 MJH Life Sciences

All rights reserved.